يعرض 1 - 6 نتائج من 6 نتيجة بحث عن '"Hullock, K"', وقت الاستعلام: 0.37s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    وصف الملف: text

    Relation: https://eprints.whiterose.ac.uk/209330/1/e083582.full.pdf; Brittain, G. orcid.org/0000-0002-9903-7203 , Petrie, J. orcid.org/0000-0001-6150-6724 , Duffy, K.E.M. et al. (25 more authors) (2024) Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. BMJ Open, 14 (2). e083582. ISSN 2044-6055

  3. 3
    Academic Journal

    المساهمون: StarMS trial team

    وصف الملف: 1 - 10 + 20 pp. of supplementary materials; Electronic

    Relation: BMJ Open; ORCiD: Gavin Brittain orcid:0000-0002-9903-7203; ORCiD: Katie Hullock orcid:0000-0001-8652-1525; ORCiD: Diana Papaioannou orcid:0000-0002-6259-0822; orcid:0000-0002-6259-0822; ORCiD: Elisa Roldan orcid:0000-0001-7242-170X; ORCiD: Gavin Giovannoni orcid:0000-0001-9995-1700; ORCiD: David Paling orcid:0000-0003-4577-1821; ORCiD: Thushan de Silva orcid:0000-0002-6498-9212; ORCiD: Annalena Venneri orcid:0000-0002-9488-2301; ORCiD: Stephen J Walters orcid:0000-0001-9000-8126; ORCiD: Carolyn Young orcid:0000-0003-1745-7720; ORCiD: Basil Sharrack orcid:0000-0003-2406-6365; ORCiD: John A Snowden orcid:0000-0001-6819-3476; e083582; Brittain, G. et al. on behalf of the StarMS trial team (2024) 'Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial', BMJ Open, 14 (2), e083582, pp. 1 - 10 (+ 20 pp. of supplementary materials). doi:10.1136/bmjopen-2023-083582.; https://bura.brunel.ac.uk/handle/2438/28470; https://doi.org/10.1136/bmjopen-2023-083582

  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Report